Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Growth in the quarter offset by loss of market exclusivity for key products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

1Q Revenues: $9.4 billion (+1%)

1Q Earnings: $1.6 billion (+38%)

Comments: Pharmaceutical sales were up 1% to $8.2 billion, driven by oncology, hepatitis C and vaccines, largely offset by the loss of market exclusivity for ZETIA, CUBICIN, and NASONEX, as well as ongoing biosimilar competition in Europe for REMICADE. Sales of these products declined $686 million during 1Q17. Sales in the diabetes franchise were also down, reflecting a decrease in JANUVIA and JANUMET due to the timing of customer purchases in the U.S. as anticipated for the quarter. Growth in oncology was due to higher sales of KEYTRUDA ($584 million, +134%). Growth in hepatitis C was driven by ZEPATIER with $378 million in sales. Growth in vaccines was primarily driven by higher sales of GARDASIL ($532 million, +41%). Animal Health sales totaled $939 million, up 13% driven by the BRAVECTO.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters